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The release of recent guidelines for high cholesterol, hypertension and diabetes in the U.S. has been accompanied
by great noise and concerns, both in the academic circuits and the lay press. For persons aged 40 to75 years, with
LDL cholesterol levels between 70–189 mg/dL and 7.5% or higher estimated 10-year risk, the peril of a global
“statinization” has been advocated, predicting a 70% increase of statin use in this otherwise healthy people. A
minority of the Eight Joint National Committee panel disagreed with the recommendation to increase the target
systolic blood pressure from 140 to 150 mmHg in persons aged 60 years or older without diabetes mellitus or chronic
kidney disease. The 2013-American Association of Clinical Endocrinologists algorithm and consensus statement on
diabetes has been criticized with particular concerns about transparency, conflicts of interest, group composition, and
the abundant use of personal judgment and experience instead of rigorous methodology. Separate careers for experts
who collect evidence from persons who write the actual guidelines seems a good opportunity in order to attenuate
the noise associated with release of new guidelines, especially those that counter prior practice.Introduction
“Patients and the public benefit when physicians and re-
searchers collaborate with pharmaceutical, medical de-
vice, and biotechnology companies to develop products
that benefit individual and public health. At the same
time, concerns are growing that wide-ranging financial
ties to industry may unduly influence professional judg-
ments involving the primary interests and goals of medi-
cine. Such conflicts of interest threaten the integrity of
scientific investigations, the objectivity of professional
education, the quality of patient care, and the public’s
trust in medicine” [1].
On 13 November 2013, from the columns of the New
York Times (http://www.nytimes.com/2013/11/14/opin-
ion/dont-give-more-patients-statins.html?_r=0), Abramson
and Redberg exhorted healthy Americans to focus on the
real factors that undeniably reduce the risk of heart disease
(healthy diets, exercise, avoiding smoking) and not on sta-
tin prevention, as suggested by the new cholesterol guide-
lines from the American College of Cardiology (ACC) and
the American Heart Association (AHA) [2]. The new, long-
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are even criticized by members of the very panel that
developed them [4]. The validity of the 2013-American
Association of Clinical Endocrinologists (AACE) algo-
rithm and consensus statement on diabetes [5] has
fiercely been questioned [6]. Are all these concerns in-
tellectually and scientifically justified, or are they re-
lated to the evidence that guidelines per se generate
controversy, given the complexity of the task and the
limitations of available evidence?
The ACC/AHA cholesterol guidelines
The ACC/AHA guidelines on the treatment of blood
cholesterol [2] recommends moderate- to high-intensity
statin therapy for primary prevention for the following
groups (class I recommendations): (1) persons with low-
density lipoprotein (LDL) cholesterol levels of 190 mg/dL
or higher; (2) persons aged 40 to75 years with type 1 or 2
diabetes; or (3) persons aged 40 to 75 years with LDL
cholesterol levels between 70 and 189 mg/dL and 7.5% or
higher estimated 10-year risk of atherosclerotic cardiovas-
cular disease. The peril of a global “statinization” of the
planet for this grey zone of cardiovascular risk has been
put forward [7], predicting an increase of healthy people
for whom statins are recommended by nearly 70 percent
(about 920 million people around the world would bel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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sales of statins approaching $1 trillion by 2020. Critics also
point out that 8 of the 15 panelists of the new cholesterol
guidelines had industry ties [8].
THE JNC8 hypertension guidelines
Only about half of patients with hypertension in the
United States actually have an systolic blood pressure
(SBP) of 140 mm Hg or less [9]. The Joint National
Committee (JNC7) Guidelines [10], released more than
a decade ago, concluded that all adult patients with
hypertension (regardless of their age) should have their
BP reduced to a SBP of lower than 140 mm Hg, with
even tighter control in patients with diabetes or renal
disease (SBP <130 mmHg). In contrast, the current rec-
ommendation [3] raises target SBP goals to 150 mm Hg
or lower in those aged 60 years or older, while eliminat-
ing the tighter control recommendations in patients with
diabetes and renal disease. A minority of the panel dis-
agreed with the recommendation to increase the target
SBP from 140 to 150 mmHg in persons aged 60 years or
older without diabetes mellitus or chronic kidney disease
[4]. Intuitively, an estimated 13 million U.S. hypertensive
treated people aged 60 years or older [11] would reduce
pill intake as the SBP goal increase from 140 to 150 mmHg.
Antihypertensive medication use may be associated with
injurious falls in the elderly, a 30% to 40% increased risk
compared with no antihypertensive medication use [12].
Moreover, the results of the ACCORD MIND [13] show
that intensive management to a target SBP of less than
120 mm Hg and fibrate therapy in the context of LDL
cholesterol level control are not effective in reducing cog-
nitive decline in persons with poorly controlled type 2 dia-
betes at high risk for cardiovascular disease.
The AACE diabetes guidelines
The 2013-AACE algorithm and consensus statement on
diabetes [5] has been criticized with particular concerns
about transparency, conflicts of interest, group compos-
ition, and the abundant use of personal judgment and
experience instead of rigorous methodology [6]. Despite
all these concerns, the ultimate feeling is that the major
concern relates to the financial ties. Most panel mem-
bers, including the chair, of the diabetes AACE guide-
lines had financial conflicts of interest [6], and many of
the financial associations were with companies that sell
diabetes medications that figure prominently in the algo-
rithm and consensus statement.
Producing guidelines: a hard job
Producing guidelines in the United States has become
increasingly more complicated and contentious. The pres-
ence of conflicts of interest is a common source of contro-
versy, with claims that recommendations are designed tofill the pockets of those who would profit from the in-
terventions advocated [14]. All this leaves patients and
clinicians perplexed and distrustful of guidelines, adding
uncertainty to an imperfect science, as Medicine is.
However, scientific U.S. guidelines deeply impact on the
prescription patterns of thousands of clinicians, and on
the health needs of millions of patients worldwide. All
the story also demonstrates that even in topic areas
(high cholesterol, hypertension, diabetes) with extensive
amounts of data and published clinical trials, crucial
evidence is still missing.
Approximately 2500 guidelines are operative in the U.
S. (www.guideline.gov) with the aim to improve clinical
guidance: about three-fifths were issued by a medical
specialty society or a professional association. Even con-
sidering overlapping and homonymy, it seems reason-
able to suppose that thousands of experts are involved in
U.S. medical guidelines. But, who is an expert? A person
who is very knowledgeable about or skilful in a particu-
lar area (Oxford Dictionaries); in the medical field, an
expert is supposed to be a clinician with a solid scientific
reputation and skilled experience in clinical care. Para-
doxically, the scientific reputation of an expert may be
based on clinical trials that are, for the most, sponsored
by industry. Putting an expert among panel members for
its capacity to attract media attention, should be nu-
anced by the high likelihood for financial conflicts of
interest. In a recent cross-sectional study [15] evaluating
45 guidelines from Danish clinical specialty societies,
96% of guidelines had one or more authors with a con-
flict of interest (independent validation), but only 2%
disclosed author conflicts of interest. Moreover, only
22% of guidelines described the methods used for guide-
line development and 24% graded the types of evidence.
A suggested way out
Is there a honorable way out? For clinicians, who are
called to operate a personal choice, based on clinical
judgment, among the many guidelines release by reputed
scientific associations; for experts, whose reputation may
suffer from these reflections; and for the millions of
people whose care may be affected. It may be hard to
imagine that professional societies and scientific organi-
zations can renounce to industry funding, especially in
times, as the present, of financial shortage. Not surpris-
ingly, important members of these societies or organiza-
tions may be the same experts called for writing guidelines.
There is agreement that “clinicians and patients are most
likely to pay attention to recommendations that are formu-
lated by independent experts without funding from indus-
try” [16]. A multidisciplinary panel with members who
have no substantial financial and intellectual conflicts of
interest is essential, also for attracting the attention of clini-
cians and patients to any clinical guideline. However, the
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unproductive, and freedom from any conflict (not only
financial) can be difficult to ascertain. The American Cancer
Society methodology aligns with the Institute of Medicine
principles for trustworthy clinical guideline development,
particularly by separating the processes of specialty input
and evidence synthesis from writing of the actual guideline
[17]. Separate careers for experts who collect evidence
from persons who write the actual guidelines seems a
good opportunity in order to attenuate the rumors associ-
ated with release of new guidelines, especially those that
counter prior practice. Inclusion of multiple stakeholders
during guideline development, evidence reviews that are
fully available for scrutiny before a guideline is finalized,
and refraining from turning the release of new or updated
guidelines into media events [14] may also help.
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